SCS Stock Overview
Stem Cells Spin S.A. opera como empresa de biotecnología en Polonia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Stem Cells Spin S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.52 |
| 52 Week High | zł0.81 |
| 52 Week Low | zł0.30 |
| Beta | 0.74 |
| 1 Month Change | 4.00% |
| 3 Month Change | 22.07% |
| 1 Year Change | 16.07% |
| 3 Year Change | -54.39% |
| 5 Year Change | 4.00% |
| Change since IPO | -76.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCS | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 10.6% | 1.1% | 0.8% |
| 1Y | 16.1% | -20.0% | 34.8% |
Rentabilidad frente al sector: SCS superó al sector Polish Biotechs , que obtuvo un rendimiento del -18.7% el año pasado.
Rentabilidad vs. Mercado: SCS obtuvo unos resultados inferiores a los del mercado Polish, que fue del 34.1% el año pasado.
Price Volatility
| SCS volatility | |
|---|---|
| SCS Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.5% |
| 10% least volatile stocks in PL Market | 3.2% |
Precio estable de las acciones: SCSha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: SCS(19%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de Polish.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Andrzej Kryzar | https://stemcellsspin.com.pl |
Stem Cells Spin S.A. opera como empresa de biotecnología en Polonia. Se dedica al desarrollo, cultivo y aplicación de células madre utilizando células madre MIC-1 para medicina humana y veterinaria, y aplicaciones dermocosméticas. La empresa ofrece biodermocosméticos bajo la marca Revitacell.
Stem Cells Spin S.A. Fundamentals Summary
| SCS fundamental statistics | |
|---|---|
| Market cap | zł21.49m |
| Earnings (TTM) | -zł154.00k |
| Revenue (TTM) | zł419.32k |
51.3x
P/S Ratio-139.6x
P/E RatioIs SCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCS income statement (TTM) | |
|---|---|
| Revenue | zł419.32k |
| Cost of Revenue | zł44.61k |
| Gross Profit | zł374.71k |
| Other Expenses | zł528.71k |
| Earnings | -zł154.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 89.36% |
| Net Profit Margin | -36.73% |
| Debt/Equity Ratio | 1.6% |
How did SCS perform over the long term?
See historical performance and comparison